Constitution Index · H.R. 8205 · 2026-04-06
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Latest official status (2026-10-14): Message on Senate action sent to the House.
Constitutional grade
A
Constitutional
The bill reauthorizes and revises federal programs supporting research and development for ALS and other neurodegenerative diseases. It operates within Congress's enumerated powers under the Spending Clause and the Patent Clause, does not infringe on any constitutional rights, respects individual sovereignty by not restricting personal freedoms, and appropriately delegates implementation to federal agencies without consolidating decision-making beyond the necessary federal role in medical research and drug regulation. The bill also includes provisions for safety monitoring and transparency, aligning with due process principles.
Article I, Section 8, Clause 1 Article I, Section 8, Clause 8
SI-generated grade · passed automated checks (real Constitution citation, language rules) · not individually reviewed by a person · methodology · Report an error: hello@valuesforamerica.com
The five checks
Enumerated powers · passes
Congress has authority under Article I, Section 8, Clause 1 (Spending Clause) to provide for the general welfare by funding medical research, and under Article I, Section 8, Clause 8 (Patent Clause) to promote the progress of science and useful arts. The bill authorizes NIH and FDA grants and partnerships, which are exercises of the spending power. It does not exceed enumerated powers.
Bill of Rights · passes
The bill does not restrict speech, religion, assembly, press, petition, the right to bear arms, or any other right protected by the Bill of Rights. It imposes no searches or seizures, no self-incrimination, no deprivation of life, liberty, or property without due process, and no cruel or unusual punishment. It is purely a funding and regulatory measure for medical research.
Individual liberty · passes
The bill does not restrict what individuals can do with their person, property, speech, labor, or belief. It facilitates access to investigational drugs and supports research, which expands individual options rather than restricting them. No compelling justification is needed because no restriction is imposed.
Decentralization · passes
The bill addresses a rare and complex disease that requires national coordination of research and regulatory oversight. An individual, family, or local community cannot handle the scale of NIH and FDA programs. States could not effectively regulate interstate drug development or ensure uniform access to investigational therapies. The federal role is appropriate and does not consolidate decision-making beyond the minimum necessary for a national health crisis.
Due process and takings · passes
The bill does not take property without just compensation. It imposes no penalties or deprivations. It includes procedural safeguards by requiring NIH to assess safety and efficacy data and to require grantees to report adverse events, and FDA to publish plans and reports, ensuring transparency and accountability. These provisions support fair and non-arbitrary government action.
Provenance
- Congress.gov: HR 8205 summary · fetched 2026-10-09 · official page ↗
Version history · never overwritten
| Grade | Graded | Rubric | Source hash | Status |
|---|---|---|---|---|
| A · #613 | 2026-10-11 | vfa-constitutional-grade/1.0 | eeeb895e1bca | current |
Cite this
Values for America. “Constitutional grade: H.R. 8205, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.” VFA Constitution Index, grade 613 (rubric vfa-constitutional-grade/1.0), graded October 11, 2026. https://www.valuesforamerica.com/constitution-index/grades/613. Accessed 2026-10-19.
Permalink: https://www.valuesforamerica.com/constitution-index/grades/613
Data: this grade as JSON · full export. Attribution required.